Heron Therapeutics, Inc.
πΊπΈUnited States
- Country
- πΊπΈUnited States
- Ownership
- Public
- Established
- 1983-01-01
- Employees
- 126
- Market Cap
- $292.7M
- Website
- http://www.herontx.com
Evaluation of the Efficacy and Safety of HTX-011 for Postoperative Analgesia Following Abdominoplasty Surgery
Phase 2
Completed
- Conditions
- Postoperative Pain
- Interventions
- First Posted Date
- 2016-02-23
- Last Posted Date
- 2023-10-04
- Lead Sponsor
- Heron Therapeutics
- Target Recruit Count
- 277
- Registration Number
- NCT02689258
A Pilot Study to Investigate the Safety, Efficacy, Pharmacokinetics and Bioavailability of HTX-011, HTX-002, or HTX-009 Administered Via Injection and/or Topical Application Following Unilateral Open Inguinal Herniorrhaphy
Phase 2
Completed
- Conditions
- Postoperative Pain
- Interventions
- First Posted Date
- 2015-07-22
- Last Posted Date
- 2023-10-04
- Lead Sponsor
- Heron Therapeutics
- Target Recruit Count
- 463
- Registration Number
- NCT02504580
A Phase 2, Two-Part Evaluation of the Efficacy and Safety of Locally Administered HTX-011 for Postoperative Analgesia Following Bunionectomy
- First Posted Date
- 2015-06-15
- Last Posted Date
- 2017-02-14
- Lead Sponsor
- Heron Therapeutics
- Target Recruit Count
- 71
- Registration Number
- NCT02471898
A Prospective, Multicenter, Study of APF530 (Granisetron) SC for Prevention of CINV in Patients Receiving HEC
Phase 3
Completed
- Conditions
- Chemotherapy-induced Nausea and Vomiting
- Interventions
- First Posted Date
- 2014-04-08
- Last Posted Date
- 2016-12-28
- Lead Sponsor
- Heron Therapeutics
- Target Recruit Count
- 942
- Registration Number
- NCT02106494
- Locations
- πΊπΈ
Arizona Oncology Associates, PC-HAL, Pheonix, Arizona, United States
πΊπΈThe Oncology Institute of Hope and Innovation, Downey, California, United States
πΊπΈCompassionate Cancer Medical Center, Riverside, California, United States
A Phase I Study of the Effects of APF530 Exposure, Granisetron and Moxifloxacin
Completed
- Conditions
- Healthy
- Interventions
- Drug: Withdraw treatment
- First Posted Date
- 2011-08-15
- Last Posted Date
- 2015-08-04
- Lead Sponsor
- Heron Therapeutics
- Target Recruit Count
- 56
- Registration Number
- NCT01416259
- Locations
- πΊπΈ
Spaulding Clinical Research, West Bend, Wisconsin, United States
APF530 or Aloxi (Palonosetron Hydrochloride) Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer
Phase 3
Completed
- Conditions
- Unspecified Adult Solid Tumor, Protocol SpecificNausea and Vomiting
- Interventions
- First Posted Date
- 2006-06-23
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Heron Therapeutics
- Target Recruit Count
- 1428
- Registration Number
- NCT00343460
- Locations
- πΊπΈ
Anniston Oncology, PC, Anniston, Alabama, United States
πΊπΈPalo Verde Hematology Oncology - Glendale, Glendale, Arizona, United States
πΊπΈArizona Clinical Research Center, Incorporated, Tucson, Arizona, United States